Presenter's Information

Name Ted Feldman
Country United States
Job Interventional Cardiologist

Other content(s) by This Presenter


Slide Presentations

  1. Pre & Post-Dilatation Strategies for DES
  2. The E-valve Edge-to-Edge Repair for Mitral Regurgitation: Design Concept and EVEREST Update
  3. PCI for Left Main & Multivessel CAD: The SYNTAX Trial
  4. i2 Late-Breaking Clinical Trials Highlights
  5. Evalve Randomized Trial Update
  6. Percutaneous Mitral Valve Repair Therapies
  7. How To Disclose and What To Be Disclosed: Conflict of Interest for Physicians and Its Implication in Clinical Trial Conduct
  8. Establishing an Interventional Program for Congenital and Structural Heart Intervention: Organizational Components, Personnel Requirements, and Institutional Hurdles
  9. Percutaneous Mitral Repair Update
  10. Percutaneous Therapy of Structural Heart Disease Using Imaging Modality
  11. What Are the Longer Term Results of Percutaneous Mitral Valve Repair? What Role Will It Play?
  12. Percutaneous Therapy for Mitral Regurgitation
  13. Trans-catheter Valve Therapies: Aortic and Mitral
  14. Counterpoint: PFO Clinical Trial Results (RESPECT and PC) Are Problematic
  15. Percutaneous Mitral Valve Repair(PMVR): From Science to Practice
  16. Con: No More Device, Lack of Evidence
  17. Case Presentation: Recurrent Cardioembolic Stroke
  18. [Are We Ready to Do Transcatheter Treatment for Mitral Regurgitation?] For: Yes! Right Now, Device and Technique Are Already Ready.
  19. Evolving Transcatheter Mitral Valve Repair and Replacement Therapies
  20. Current Status of Transcatheter Therapies for Mitral Regurgitation
  21. LAA Closure: Technical Tips and Lessons from Nightmare Cases
  22. The Lotus Valve: Minimization of Paravalvular Leak with a Repositionable Next Generation TAVR Device
  23. Wide Application of Percutaneous LAA Closure: Too Much Early?
  24. Transcatheter Mitral Valve Therapies: New Advances in Techniques and Devices
  25. Mitral Clip 2016: Indication, Clinical Data and Limitations
  26. WATCHMAN Device Versus NOAC (New Oral Anticoagulant) Drugs
  27. MitraClip Will Be the Dominant Therapy in Severe FMR - Predicting COAPT
  28. WATCHMAN Device: Current Application and Future Indications
  29. Percutaneous Mitral/Tricuspid Repair; State-of-the Art and Future Directions
CardioVascular Research Foundation (CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea
Tel_82.2.3010.4792 | Fax_82.2.475.6898
재단법인 심장혈관연구재단
대표이사 박승정 | 서울시 송파구 올림픽로43길 88, 서울아산병원 아산교육연구관 2층 | 사업자등록번호 215-82-06387
개인정보 관리책임자_노순정 | 전화번호_02.3010.4792 | 팩스번호_02.475.6898
Copyright © CVRF, Seoul, Korea. All rights reserved.